

Special Issue

Immunological Studies in Human Aging

Message from the Guest Editor

Dear Colleagues We are pleased to invite you to submit your work to *Vaccines* in this Special Issue on immunological studies in human aging. Increased longevity in humans is multifactorial but significantly originates from sustaining immunity from early life to the end of life. This Special Issue aims to highlight novel studies, state-of-the-art reviews, and meta-analyses in the field of immunology in human aging.

Responsiveness to vaccination, novel vaccination strategies, and the understanding of immunological processes in the context of human aging are topics of interest. New findings on the role of immune cell populations, soluble factors (cytokines, chemokines), and other soluble factors (extracellular vesicles) of the innate and adaptive immune system are welcomed. Contributions of technological advances (immunoassays, data analysis) in this field will also be considered. Submissions related to the response to vaccination in older adults in the context of infectious diseases but also cancer are highly encouraged. We look forward to receiving your contributions.

Guest Editor

Dr. Anis Larbi

1. Medical and Scientific Affairs, Beckman Coulter Life Sciences, 93420 Villepinte, France
2. Faculty of Medicine, University of Sherbrooke, Sherbrooke, QC J1H 5N4, Canada

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/151410

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).